Figure 5. Comparison of staining score of CD90 expression among normal pancreas, cancer adjacent normal tissue, chronic pancreatitis, benign islet tumor, PDAC of stage I, II, and III/IV, and metastatic tumor.

P-values were determined in ANCOVA by comparing IHC scores between each group, adjusted for age and gender, and the multiple comparisons are accounted for using the Tukey's method. The CD90 staining score was distinctly higher in PDAC of all stages compared to those in non-malignant cases (p<0.0001). Samples with metastatic tumors also showed increased expression of CD90 than in non-malignant cases (p<0.05). (*: p<0.05; ****: p<0.0001).